Schedule III Improves Cash Flow — Not Cannabis’ Risk Profile

President Donald Trump’s executive order directing the reclassification of cannabis from Schedule I to Schedule III marks the most significant federal cannabis policy shift in U.S. history. But while the move is historic, its real impact is narrower, more technical, and more conditional than many early reactions suggest.

Rescheduling does not legalize cannabis. It does not open national banking overnight. And it does not erase regulatory risk. What it does do is materially change the financial profile of compliant operators while simultaneously raising expectations around governance, compliance, and institutional readiness.

For investors and operators, Schedule III is best understood as a cash-flow event, not a risk reset.

The Core Financial Shift: 280E Relief

The most immediate and concrete impact of rescheduling is the removal of IRS Section 280E, which has prevented state-legal cannabis businesses from deducting ordinary operating expenses. That single change alters after-tax cash flow, which in turn affects valuation, debt capacity, and transaction flexibility.

Darren Gleeman, Managing Partner at MBO Ventures, framed the impact plainly:

“The real financial impact of Schedule III is not symbolic, it is economic. Removing 280E improves after-tax cash flow, which is the foundation of valuation, debt capacity, and exit flexibility.”

Gleeman cautioned, however, that this shift will not trigger an instant capital surge.

“That shift is likely to bring private credit and deal activity back gradually, not overnight, but meaningfully.”

In other words, rescheduling improves fundamentals, but it does not eliminate underwriting discipline.

Normalization Raises the Bar, Not the Ceiling

Several industry leaders emphasized that Schedule III represents normalization, not deregulation.

Marc Rodriguez, Co-Founder and CEO of Green Leaf Business Solutions, described rescheduling as a test of operational maturity:

“Rescheduling cannabis marks a moment of normalization, not just a policy shift. As the industry becomes more institutionalized, expectations rise alongside opportunity, particularly around governance, transparency, and operational discipline.”

Rodriguez added that while the change rewards strong operators, it will also expose weak ones.

“This change will reward operators that already function like legitimate businesses with scalable infrastructure and strong internal controls. At the same time, it introduces greater scrutiny that will expose structural weaknesses across the market.”

Banking Reality Check: Scrutiny Increases, Not Decreases

One of the most persistent misconceptions surrounding Schedule III is that it clears the path for frictionless banking. Industry experts warn that this assumption is misguided.

Kevin Hart, Founder and CEO of Green Check, addressed the issue directly:

“Rescheduling cannabis to Schedule III should not be confused with a green light for open banking. Financial institutions have been engaging with the industry for years, and this change will not reduce scrutiny, it will increase it.”

Hart emphasized that normalization at the federal level comes with higher regulatory expectations across the financial system.

“The real risk is not the rule change itself, but being unprepared as new and overlapping regulations emerge. Institutions that lead with compliance and plan ahead will be best positioned as the market expands.”

For investors, this signals that compliance infrastructure is no longer optional or deferrable.

Capital Will Re-Enter Selectively

While Schedule III may encourage institutional re-engagement, capital is expected to return cautiously and unevenly.

Will Read, Founder and CEO of CannaPlanners, described rescheduling as a long-term signal rather than a short-term catalyst:

“This move reframes cannabis from a fringe political issue into a legitimate industry that demands modern regulatory infrastructure, clearer capital pathways, and long-term planning.”

Read noted that the real impact will appear structurally, not immediately.

“The real impact will show up in how investors, institutional partners, and regulators reassess risk, not overnight, but structurally.”

Compliance, Data, and Supply Chain Discipline

As cannabis becomes more normalized at the federal level, expectations around traceability, reporting, and operational rigor increase.

Nohtal Partansky, Co-Founder and CEO of Sorting Robotics, pointed to downstream implications for infrastructure investment:

“Rescheduling to Schedule III signals that cannabis is being treated as a complex, regulated system, which creates momentum for better data, traceability, and consistent standards.”

Partansky added that the benefit is not immediate relief, but long-term durability.

“The real impact is not immediate relief, but the incentive to invest in durable, precise infrastructure that supports a dependable and transparent supply chain.”

The FDA Question and Regulatory Tradeoffs

Some operators also cautioned that rescheduling may introduce new regulatory complexity, particularly through potential FDA involvement.

Johnathan McFarlane, VP of Sales and Marketing at RollPros, highlighted that risk:

“If and when it is formally rescheduled, that means the FDA will likely get involved, which isn’t necessarily a good thing for our industry.”

McFarlane noted that drug rescheduling is rare and often slow.

“This isn’t a process that happens often, and will surely come with speed bumps.”

Industry Confidence, With Caveats

Despite the limitations, many industry leaders see rescheduling as a necessary step toward long-term stability.

Keith Cich, Co-Founder and CFO of Sunderstorm, said the shift could help attract new capital to the sector:

“Most importantly, this shift may help steer new investors toward a capital-starved industry.”

But Cich emphasized that rescheduling is not a complete solution.

“That said, it’s not a cure-all—without a national framework for interstate commerce, operators will continue to face challenges generating sustainable profits.”

Tim Barash, Chairman and CEO of Dutchie and Co-chair of the Coalition for Cannabis Scheduling Reform, described the broader implications:

“Moving cannabis to Schedule III represents a fundamental shift in how the federal government and society at large view the plant, transforming the way the cannabis industry operates.”
Barash pointed to 280E relief as one of the most immediate changes, while also highlighting longer-term cultural effects.

“When federal policy catches up to reality, it changes how consumers, families, and patients think about cannabis. That matters just as much as the business impact.”

Bottom Line

Schedule III materially improves cash flow for compliant cannabis operators. It strengthens balance sheets, improves underwriting assumptions, and restores financial logic to an industry long distorted by federal tax policy.

What it does not do is eliminate regulatory risk, accelerate legalization, or guarantee capital inflows.

For investors, the message is clear: rescheduling rewards discipline, preparedness, and operational maturity, not speculation.

The rules of the game are not being rewritten. They are being enforced more seriously.

Photo by Jorge Campos on Unsplash